Pan Drugs
In the Dec 2015 quarter, revenue rose 1.1% year on year to ₹5.58 Cr and net profit was −₹0.08 Cr, against ₹0.50 Cr a year earlier (compared with Dec 2014). Promoters held 39.36% of Pan Drugs in Dec 2017, unchanged from Sep 2017.
Peer Comparison
Healthcare › Pharmaceuticals & Biotechnology › Pharmaceuticals
| ₹1,766.50 | 35.04 | 4,23,843 Cr | 5.07 | 0.91% | 13.79% | 17.94% | 61,848 Cr | 12,117 Cr | |
| ₹9,631.00 | 87.41 | 2,55,673 Cr | 15.25 | 0.32% | 15.32% | 18.96% | 11,682 Cr | 2,925 Cr | |
| ₹4,596.50 | 72.16 | 1,74,836 Cr | 9.52 | 0.82% | 12.16% | 9.06% | 17,058 Cr | 2,156 Cr | |
| ₹2,183.50 | 107.88 | 1,17,977 Cr | 22.26 | 0.09% | 16.38% | 19.67% | 7,323 Cr | 1,090 Cr | |
| ₹1,180.90 | 26.28 | 1,17,795 Cr | 4.35 | 0.09% | 16.99% | 19.24% | 28,515 Cr | 4,593 Cr | |
| ₹1,340.80 | 34.73 | 1,11,914 Cr | 2.88 | 0.61% | 10.87% | 13.94% | 34,247 Cr | 3,184 Cr | |
| ₹1,370.80 | 32.84 | 1,10,741 Cr | 3.13 | 0.96% | 11.21% | 14.88% | 28,589 Cr | 3,356 Cr | |
Pan Drugs (this company) | — | — | — | — | — | — | — | 35 Cr | — |
| Median 8 companies | ₹1,766.50 | 35.04 | 1,17,977 Cr | 5.07 | 0.61% | 13.79% | 17.94% | 22,787 Cr | 3,184 Cr |
Comparable companies in the same industry. Market cap, P/E and P/B use the live price; other metrics are as reported in filings. A dash means the figure is not published for that company.
Tapetide Score
Data-driven rating, 0–100. How it works →
No Tapetide Score has been computed for this stock yet.
Key Insights
Weaknesses
1- Company has low interest coverage ratio.
Growth Rate
change over 1 year
Quarterly Results
| Particulars | Jun 2013 | Sep 2013 | Dec 2013 | Mar 2014 | Jun 2014 | Sep 2014 | Dec 2014 | Mar 2015 | Jun 2015 | Sep 2015 | Dec 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 5.39 | 9.67 | 8.89 | 7.44 | 8.41 | 12.49 | 5.52 | 8.92 | 6.45 | 4.15 | 5.58 |
| Expenses | 4.26 | 9.6 | 8.48 | 7.84 | 8.3 | 12.28 | 4.86 | 9.14 | 6.2 | 4.13 | 5.53 |
| Operating Profit | 1.13 | 0.07 | 0.41 | -0.4 | 0.11 | 0.21 | 0.66 | -0.22 | 0.25 | 0.02 | 0.05 |
| OPM % | 20.96% | 0.72% | 4.61% | -5.38% | 1.31% | 1.68% | 11.96% | -2.47% | 3.88% | 0.48% | 0.9% |
| Other Income | -0.02 | 0.02 | 0.2 | 0.09 | 0.01 | 0.02 | 0.05 | 0.33 | 0.04 | 0.05 | 0.07 |
| Interest | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0 | 0.01 | 0.01 |
| Depreciation | 0.14 | 0.15 | 0.16 | 0.15 | 0.15 | 0.15 | 0.2 | 0.71 | 0.19 | 0.19 | 0.19 |
| PBT | 0.96 | -0.07 | 0.44 | -0.47 | -0.04 | 0.07 | 0.5 | -0.61 | 0.1 | -0.13 | -0.08 |
| Tax % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Profit | 0.96 | -0.06 | 0.44 | -0.47 | -0.05 | 0.07 | 0.5 | -0.61 | 0.1 | -0.13 | -0.08 |
| EPS (₹) | 3.05 | -0.19 | 1.4 | -1.5 | -0.16 | 0.22 | 1.59 | -1.94 | 0.32 | -0.41 | -0.25 |
Profit & Loss
| Particulars | TTM |
|---|---|
| Sales | 25.1 |
| Expenses | 25 |
| Operating Profit | 0.1 |
| OPM % | 0.4% |
| Other Income | 0.49 |
| Interest | 0.03 |
| Depreciation | 1.28 |
| PBT | -0.72 |
| Net Profit | -0.72 |
| EPS (₹) | -2.28 |
Balance Sheet
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 5 | 5 | 5 | 5 |
| Reserves | 52 | 43 | 35 | 33 | 40 | 56 | 74 | 93 | 108 | 124 | 137 | 139 |
| Borrowings | 0 | 0 | 2 | 5 | 5 | 3 | 2 | 1 | 0 | 0 | 0 | 0 |
| Other Liabilities | 14 | 11 | 15 | 12 | 8 | 10 | 21 | 18 | 20 | 23 | 33 | 32 |
| Total Liabilities | 70 | 58 | 56 | 55 | 58 | 74 | 102 | 117 | 133 | 152 | 174 | 177 |
| Fixed Assets | 4 | 3 | 7 | 3 | 3 | 3 | 3 | 3 | 4 | 18 | 19 | 26 |
| CWIP | 0 | 0 | 1 | 2 | 0 | 0 | 6 | 12 | 19 | 5 | 4 | 0 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 66 | 56 | 48 | 50 | 55 | 72 | 93 | 101 | 109 | 129 | 151 | 151 |
| Total Assets | 70 | 58 | 56 | 55 | 58 | 74 | 102 | 117 | 133 | 152 | 174 | 177 |
Cash Flow
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating | -16 | -14 | 12 | -13 | 1 | 6 | 11 | 24 | -4 | 28 | 2 |
| Investing | 1 | 3 | -4 | 4 | -2 | 0 | 0 | -12 | -7 | -23 | 10 |
| Financing | 14 | 4 | -2 | 3 | -2 | -1 | -4 | -2 | 1 | -1 | -5 |
| Net Cash Flow | 0 | -7 | 6 | -6 | -2 | 4 | 8 | 9 | -10 | 4 | 7 |
Ratios
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 218 | 222 | 105 | 173 | 187 | 182 | 269 | 194 | 216 | 143 | 164 |
| Cash Conversion Cycle | 218 | 222 | 105 | 173 | 187 | 182 | 269 | 194 | 216 | 143 | 164 |
| Working Capital Days | 146 | 157 | 42 | 191 | 188 | 212 | 210 | 172 | 221 | 142 | 148 |
| ROCE % | — | -15% | -6% | 9% | 23% | 39% | 31% | 28% | 16% | 17% | 15% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Pan Drugs insights
36 extracted metrics + investor summaries across FY14–FY26.
Documents
Frequently Asked Questions about Pan Drugs
Where is Pan Drugs Ltd (531440) listed?
Which sector does Pan Drugs Ltd belong to?
Company Information
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/531440.md for Pan Drugs Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.
Append .md to any Tapetide URL for the
same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For
live, structured queries instead of documents, use our Indian stock market MCP server.